| __timestamp | Amneal Pharmaceuticals, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 335989000 | 520990000000 |
| Thursday, January 1, 2015 | 367054000 | 535405000000 |
| Friday, January 1, 2016 | 420770000 | 558755000000 |
| Sunday, January 1, 2017 | 507476000 | 495921000000 |
| Monday, January 1, 2018 | 946588000 | 659690000000 |
| Tuesday, January 1, 2019 | 1273376000 | 1089764000000 |
| Wednesday, January 1, 2020 | 1364130000 | 994308000000 |
| Friday, January 1, 2021 | 1324696000 | 1106846000000 |
| Saturday, January 1, 2022 | 1427596000 | 1244072000000 |
| Sunday, January 1, 2023 | 1573042000 | 1431505000000 |
| Monday, January 1, 2024 | 1431505000000 |
Unveiling the hidden dimensions of data
In the competitive world of pharmaceuticals, cost efficiency is a critical factor for success. This analysis compares the cost of revenue efficiency between Takeda Pharmaceutical Company Limited and Amneal Pharmaceuticals, Inc. from 2014 to 2023. Takeda, a global leader, consistently shows a robust cost of revenue, peaking at approximately 1.43 trillion in 2023, reflecting a 175% increase since 2014. In contrast, Amneal, a smaller player, demonstrates a steady growth trajectory, with its cost of revenue rising by 368% over the same period, reaching 1.57 billion in 2023. This stark contrast highlights Takeda's dominance in scale, while Amneal's rapid growth underscores its aggressive market strategy. Notably, data for Amneal in 2024 is missing, suggesting potential volatility or reporting delays. This comparison offers a fascinating glimpse into the strategic financial maneuvers of these pharmaceutical titans.
Comparing Cost of Revenue Efficiency: Novo Nordisk A/S vs Takeda Pharmaceutical Company Limited
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Ionis Pharmaceuticals, Inc.
Cost of Revenue Comparison: Takeda Pharmaceutical Company Limited vs Xenon Pharmaceuticals Inc.
Cost Insights: Breaking Down Takeda Pharmaceutical Company Limited and HUTCHMED (China) Limited's Expenses
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Mesoblast Limited
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue Trends: Incyte Corporation vs Amneal Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Exelixis, Inc. vs Amneal Pharmaceuticals, Inc.
Cost of Revenue Comparison: Alkermes plc vs Amneal Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Amneal Pharmaceuticals, Inc. and PTC Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Amneal Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored